868peffectiveness of Combination Gemcitabine/paclitaxel after Failure of Platinum-based Chemotherapy for Metastatic Urothelial Cancer.
نویسندگان
چکیده
M. Brandão1, C. Camacho2, C. Faustino3, N. Sousa4, J. Mauricio2 Serviço de Oncologia Médica, Instituto Portugues de Oncologia Centro do Porto (IPO-Porto), Porto, PORTUGAL Medical Oncology Department, Instituto Portugues de Oncologia Centro do Porto(IPO-Porto), Porto, PORTUGAL Medical Oncology/ Hematology, Instituto Portugues de Oncologia Centro do Porto, Porto, PORTUGAL Medical Oncology/ Hematology, Portuguese Institute of Oncology of Oporto, Oporto, PORTUGAL
منابع مشابه
Combination of gemcitabine and paclitaxel as second-line chemotherapy for advanced urothelial carcinoma.
OBJECTIVE The aim of this study was to evaluate the efficacy and toxicities of the gemcitabine and paclitaxel combination regimen as second-line chemotherapy for patients with advanced or metastatic urothelial carcinoma (UC) who have previously been treated with platinum-based chemotherapy for the metastatic disease. METHODS Thirty-three patients with advanced or metastatic UC who had receive...
متن کاملLong Term Progression Free Survival Achieved by Maintenance “Second–Line” Polychemotherapy with Gemcitabine/Paclitaxel in Metastatic Urothelial Cancer of the Renal Pelvis—A Case Report
Moderate activity of systemic chemotherapy for advanced urothelial cancer has been reported for more than 30 years. Only with the advent of potent combination therapy clinically significant response rates as well as prolonged survival were documented. The therapeutic effect of a “second-line” polychemotherapy in metastatic upper tract urothelial cancer is largely unknown caused by the small num...
متن کاملPaclitaxel plus doxorubicin chemotherapy as second-line therapy in patients with advanced urothelial carcinoma pretreated with platinum plus gemcitabine chemotherapy.
BACKGROUND We retrospectively evaluated the efficacy and toxicity of paclitaxel plus doxorubicin as a second-line treatment in patients with urothelial carcinoma, who had not responded to a prior platinum plus gemcitabine combination. PATIENTS AND METHODS All patients received intravenous infusions of paclitaxel (175 mg/m(2)/h) and doxorubicin (50 mg/m(2)/30 min) on day 1. Chemotherapy course...
متن کاملA pilot study of gemcitabine and paclitaxel as third-line chemotherapy in metastatic urothelial carcinoma
Background: We evaluated the effectiveness of gemcitabine and paclitaxel therapy in patients with metastatic urothelial carcinoma for whom two lines of sequential chemotherapy had been unsuccessful. Methods: A total number of 105 patients who had previously received first-line chemotherapy consisting of gemcitabine and cisplatin or carboplatin, were treated with second-line gemcitabine and doce...
متن کاملCombination of gemcitabine and paclitaxel is a favorable option for patients with advanced or metastatic urothelial carcinoma previously treated with cisplatin-based chemotherapy.
OBJECTIVE To evaluate the efficacy and toxicity of a gemcitabine and paclitaxel regimen for patients with advanced urothelial carcinoma who had previously been treated with methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy, and to determine the prognostic factors for survival in second-line chemotherapy. METHODS From June 2005 to April 2010, 24 eligible patients who had previo...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Annals of oncology : official journal of the European Society for Medical Oncology
دوره 25 suppl_4 شماره
صفحات -
تاریخ انتشار 2014